Optiscan has been featured in Stockhead’s Health & Biotech Investor Guide 2026, in an in-depth profile examining how delays in traditional pathology continue to influence surgical decision-making — and how real-time cellular imaging could redefine that paradigm.

The article explores how Optiscan is advancing its confocal laser endomicroscopy platforms to provide surgeons and pathologists with live, cellular-level visualisation during procedures, rather than days later through conventional slide-based workflows.

The feature highlights progress across the InVue® precision surgery and InForm® digital pathology platforms, including ongoing breast cancer studies at Royal Melbourne Hospital, a head and neck cancer study at St John of God Murdoch Hospital, pathology validation work with Australian Clinical Labs, and preparations for similarly designed U.S. studies at the Mayo Clinic.

In what is described as a pivotal year for the company, the article outlines expectations to lodge multiple applications with the U.S. Food and Drug Administration, supported by clinical data being generated across Australia and the United States.

The profile also notes Dr Camile Farah’s invitation to deliver the keynote address at the Mayo Clinic’s Beahrs Surgical Innovation Summit, reflecting growing international recognition of Optiscan’s technology and progress.

“It was an honour and privilege and shows Mayo’s faith in a small Australian company,” said Dr Farah.

Stockhead – Health & Biotech Investor Guide 2026 – Read the full article here.